<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559962</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-004</org_study_id>
    <nct_id>NCT00559962</nct_id>
  </id_info>
  <brief_title>Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin,
      ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic
      Resonance Spectroscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal within the current development program and this study is to investigate whether
      lower doses of AEGR-733 can result in significant reductions in LDL-C and TGs while providing
      fewer gastrointestinal adverse events and less hepatic fat accumulation than seen in studies
      with higher doses. The potential for atorvastatin, ezetimibe or the PPAR-alpha agonist
      (fenofibrate) to ameliorate any hepatic fat accumulation will also be investigated. The
      twelve week dosing schedule allows us to demonstrate the longer term effects of lower doses
      of MTP-I on hepatic fat accumulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Percent Hepatic Fat</measure>
    <time_frame>Baseline and 12 weeks on study drug</time_frame>
    <description>Absolute change from Baseline in percent hepatic fat</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Percent Hepatic Fat</measure>
    <time_frame>Baseline and 12 weeks on study drug</time_frame>
    <description>Absolute change from Baseline in percent hepatic fat</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg AEGR-733</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg AEGR-733</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7.5 mg AEGR-733</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg AEGR-733</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg AEGR-733 + 20 mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg AEGR-733 + 145 mg fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg AEGR-733 + 10 mg ezetimibe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 and atorvastatin</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 and fenofibrate</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEGR-733 and ezetimibe</intervention_name>
    <description>3 capsules each evening for each 4-week period</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. LDL-C between 100 and 190 mg/dL

          2. Hepatic fat under 6.2% per MRS

        Exclusion Criteria:

          1. Pregnant or lactating females

          2. Uncontrolled hypertension &gt;180/95 mmHg

          3. Chronic renal insufficiency - serum creatinine &gt;2.5 mg/dL at screen

          4. Liver disease; i.e., hepatitis, cirrhosis

          5. Major surgery within 3 months of screen

          6. Cardiac insufficiency

          7. Hx of malignancy other than basal or squamous cell within past 5 yrs

          8. Participation in any investigational drug study within 6 wks of screen

          9. Prior exposure to AEGR-733 in past 12 months

         10. Serious or unstable medical or psychological conditions

         11. More than one alcoholic drink per day

         12. Regular consumption of grapefruit juice or meds known to be metabolized by CYP 3A4

         13. Currently taking corticosteroids

         14. Other lipid-lowering meds (washout permitted)

         15. Fish oil, niacin grater than 200 mg/day and herbal weight loss products (washout
             permitted)

         16. Acute CVD or event within previous 6 months

         17. Diabetes Mellitus

         18. Hepatitis B or C

         19. Medicated COPD

         20. Idiopathic pulmonary fibrosis

         21. G.I. disorders that cause chronic diarrhea

         22. Fasting triglycerides =/&gt; 400 mg/dL

         23. Body Mass Index &gt; 35kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Sasiela, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aegerion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMARC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Research Associates</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Trends Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ. School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2007</study_first_posted>
  <results_first_submitted>January 18, 2013</results_first_submitted>
  <results_first_submitted_qc>January 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2013</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <name_title>William J Sasiela, PhD Chief Medical Officer</name_title>
    <organization>Aegerion Pharmaceuticals</organization>
  </responsible_party>
  <keyword>LDL</keyword>
  <keyword>hepatic fat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed from 06 Sept 2007 to 05 Sept 2008. A total of 16 medical clinics participated in the study.</recruitment_details>
      <pre_assignment_details>Subjects underwent a 5- to 9-week screening washout period to determine study eligibility and to wash-out patients of all lipid-lowering therapies; patients were required to have low-density lipoprotein cholesterol (LDL-C) between 100 and 190 mg/dL (average of 2 visits during screening) and hepatic fat less than 6.2% for randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral placebo every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>AEGR-733 2.5 mg</title>
          <description>Oral lomitapide 2.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>AEGR-733 5 mg</title>
          <description>Oral lomitapide 5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>AEGR-733 7.5 mg</title>
          <description>Oral lomitapide 7.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>AEGR-733 10 mg</title>
          <description>Oral lomitapide 10 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P6">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>Oral lomitapide 5 mg + atorvastatin 20 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P7">
          <title>AEGR-733 5 mg + Fenofibrate 145 mg</title>
          <description>Oral lomitapide 5 mg + micronized fenofibrate 145 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="P8">
          <title>AEGR-733 5 mg + Ezetimibe 10 mg</title>
          <description>Oral lomitapide 5 mg + ezetimibe 10 mg every 4 weeks for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="35"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="33"/>
                <participants group_id="P8" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="28"/>
                <participants group_id="P8" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral placebo every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>AEGR-733 2.5 mg</title>
          <description>Oral lomitapide 2.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>AEGR-733 5 mg</title>
          <description>Oral lomitapide 5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>AEGR-733 7.5 mg</title>
          <description>Oral lomitapide 7.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>AEGR-733 10 mg</title>
          <description>Oral lomitapide 10 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>Oral lomitapide 5 mg + atorvastatin 20 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B7">
          <title>AEGR-733 5 mg + Fenofibrate 145 mg</title>
          <description>Oral lomitapide 5 mg + micronized fenofibrate 145 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B8">
          <title>AEGR-733 5 mg + Ezetimibe 10 mg</title>
          <description>Oral lomitapide 5 mg + ezetimibe 10 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="34"/>
            <count group_id="B5" value="35"/>
            <count group_id="B6" value="28"/>
            <count group_id="B7" value="33"/>
            <count group_id="B8" value="29"/>
            <count group_id="B9" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="12.53"/>
                    <measurement group_id="B2" value="51.5" spread="12.99"/>
                    <measurement group_id="B3" value="48.6" spread="11.3"/>
                    <measurement group_id="B4" value="49.0" spread="10.24"/>
                    <measurement group_id="B5" value="52.9" spread="11.97"/>
                    <measurement group_id="B6" value="53.9" spread="8.92"/>
                    <measurement group_id="B7" value="54.0" spread="11.95"/>
                    <measurement group_id="B8" value="52.7" spread="9.36"/>
                    <measurement group_id="B9" value="51.3" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="33"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Percent Hepatic Fat</title>
        <description>Absolute change from Baseline in percent hepatic fat</description>
        <time_frame>Baseline and 12 weeks on study drug</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>AEGR-733 5 mg</title>
            <description>Oral lomitapide 5 mg every 4 weeks for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Percent Hepatic Fat</title>
          <description>Absolute change from Baseline in percent hepatic fat</description>
          <population>ITT</population>
          <units>Percent of Hepatic Fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.814"/>
                    <measurement group_id="O2" value="4.72" spread="6.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-way analysis of variance (ANOVA) to compare the absolute change from baseline to Week 12 in percent hepatic fat between AEGR-755 5 mg and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.30</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Percent Hepatic Fat</title>
        <description>Absolute change from Baseline in percent hepatic fat</description>
        <time_frame>Baseline and 12 weeks on study drug</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>AEGR-733 2.5 mg</title>
            <description>Oral lomitapide 2.5 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>AEGR-733 5 mg</title>
            <description>Oral lomitapide 5 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>AEGR-733 7.5 mg</title>
            <description>Oral lomitapide 7.5 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>AEGR-733 10 mg</title>
            <description>Oral lomitapide 10 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
            <description>Oral lomitapide 5 mg + atorvastatin 20 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O7">
            <title>AEGR-733 5 mg + Fenofibrate 145 mg</title>
            <description>Oral lomitapide 5 mg + micronized fenofibrate 145 mg every 4 weeks for 12 weeks</description>
          </group>
          <group group_id="O8">
            <title>AEGR-733 5 mg + Ezetimibe 10 mg</title>
            <description>Oral lomitapide 5 mg + ezetimibe 10 mg every 4 weeks for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Percent Hepatic Fat</title>
          <description>Absolute change from Baseline in percent hepatic fat</description>
          <population>ITT</population>
          <units>Percent of Hepatic Fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.814"/>
                    <measurement group_id="O2" value="4.95" spread="7.122"/>
                    <measurement group_id="O3" value="4.72" spread="6.297"/>
                    <measurement group_id="O4" value="3.94" spread="5.763"/>
                    <measurement group_id="O5" value="7.86" spread="9.515"/>
                    <measurement group_id="O6" value="3.68" spread="5.365"/>
                    <measurement group_id="O7" value="7.70" spread="9.390"/>
                    <measurement group_id="O8" value="7.55" spread="6.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA to compare the absolute change from baseline to Week 12 in percent hepatic fat between active treatment groups and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.27</ci_lower_limit>
            <ci_upper_limit>7.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.30</ci_lower_limit>
            <ci_upper_limit>7.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA to compare the absolute change from baseline to Week 12 in percent hepatic fat between active treatment groups and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.73</ci_lower_limit>
            <ci_upper_limit>6.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.31</ci_lower_limit>
            <ci_upper_limit>11.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA to compare the absolute change from baseline to Week 12 in percent hepatic fat between active treatment groups and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.58</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA to compare the absolute change from baseline to Week 12 in percent hepatic fat between active treatment groups and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.22</ci_lower_limit>
            <ci_upper_limit>11.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>One-way ANOVA to compare the absolute change from baseline to Week 12 in percent hepatic fat between active treatment groups and placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>(All comparisons)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.16</ci_lower_limit>
            <ci_upper_limit>9.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From 10 days before the first dose to 30 days post last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral placebo every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>AEGR-733 2.5 mg</title>
          <description>Oral lomitapide 2.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>AEGR-733 5 mg</title>
          <description>Oral lomitapide 5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>AEGR-733 7.5 mg</title>
          <description>Oral lomitapide 7.5 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>AEGR-733 10 mg</title>
          <description>Oral lomitapide 10 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E6">
          <title>AEGR-733 5 mg + Atorvastatin 20 mg</title>
          <description>Oral lomitapide 5 mg + atorvastatin 20 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E7">
          <title>AEGR-733 5 mg + Fenofibrate 145 mg</title>
          <description>Oral lomitapide 5 mg + micronized fenofibrate 145 mg every 4 weeks for 12 weeks</description>
        </group>
        <group group_id="E8">
          <title>AEGR-733 5 mg + Ezetimibe 10 mg</title>
          <description>Oral lomitapide 5 mg + ezetimibe 10 mg every 4 weeks for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammatory Bowel Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Eruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Protein Urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>C-reactive Protein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can publish after sponsor reviews the proposed publication. PI must give sponsor at least 60 days to review before publication. PI needs to obtain sponsor’s prior written consent to publish confidential information, which shall not be unreasonably withheld or delayed. The PI shall, upon request of sponsor, delete any confidential information which would prejudice the securing of adequate intellectual property protection from the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Sumeray, MD, Chief Medical Officer</name_or_title>
      <organization>Aegerion Pharmaceuticals</organization>
      <phone>617-500-7867</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

